AI isn’t just shaping biotech narratives | Transcript


[00:00:06] Rishi Jaluria: All right, welcome back to Strategic Alternatives, the RBC Capital Markets podcast. Please listen to the end of the podcast for important disclaimers. I'm your host for this episode, Rishi Jhaluria, Managing Director of Software Equity Research here at RBC. Today, we're going to be discussing how AI is no longer just shaping biotech innovation narratives, but is increasingly becoming a driver of biotech market performance itself. We explored this idea in our recent report, Does Healthcare Dream of Electric Sheep? published as part of our RBC Imagine research series that brings together perspective from across sectors to examine some of the biggest themes reshaping the economy and markets. Joining me today to walk through is co-author of this report, Leonid Timashev, biotech analyst at RBC Capital Markets. Leonid, welcome to the podcast.

[00:00:54] Leonid Timashev: Great to be here.

[00:00:55] Rishi Jaluria: All right, why don't we start with what sparked the report in the first place? What were you seeing in the market that suggested something had changed in the relationship between AI and biotech?

[00:01:05] Leonid Timashev: So I think, bigger picture, one of the reasons we wanted to do this report is there's a lot of factors that biotech investors have to keep in mind. These include interest rates, government policy. One thing we thought wasn't being fully appreciated was the impacts of AI, the AI trade and fund flows there. And what we really wanted to do is understand if there was a relationship, because looking at those index moves seemed to suggest there was. And as we dived in, we were able to confirm that there in fact was a relationship. It historically had been a positive one, but recently, which is very interesting, it moved to an inverse correlation. So from March 30th to August 10th, biotech industry experienced a pretty significant run-up, which at times correlated with the downturns in some of the semis and AI names. So we had initially thought that that could have been due to the historical factors that are driving biotech, M&A, FDA flexibility, stability on the policy front, drug pricing being not as much of a concern. But as we continue to dig further into this, we realized that this could be in fact due to fund flows out of semis and AI and back into biotech.

[00:02:20] Rishi Jaluria: So, are we looking at what is a temporary market dynamic, or do you think that this is something more structural that we're seeing happen?

[00:02:28] Leonid Timashev: Yeah, that's another really great question. And honestly, it's hard to know the answer to that. I think on the structural side, what we do know is that this is a recent change, and the relationship is strongest with names that are larger-cap biotech and less significant with some of the smaller-cap names. So, trying to parse that through, it might be because some of the larger biotech names are more liquid, they can accept some of the fund flows. It's seen as a defensive industry and better hedge maybe against what may be happening in AI and semiconductor, at least compared to some of the small-cap names. You know, whether this is temporary or longer term really is going to depend on AI and semis, but also with the biotech industry as a whole, both having to do with, can AI scale? Is biotech going to continue to be viewed defensively? Is it going to be impacted by rates and policy? So, that's how I'm thinking about what's happening. But, would love to hear your perspective on it. You know, why would an AI shock ripple into biotech?

[00:03:34] Rishi Jaluria: Yeah, absolutely. Look, as a software analyst, I've obviously been kind of seeing the forefront of how AI ripples into not just my sector and other pockets of tech, but just the broader economy. And look, I think the crux of the inversion is probably pretty straightforward in my mind. When the AI trade comes under pressure, capital starts to leave the kind of high volatility tech complex and looks for more alternative areas of the market. And I think when we see these periods of uncertainty, we see investors often gravitate towards sectors that look a little bit more defensive, have less direct exposure to the forces that are driving the AI trade. And as a result, that creates the conditions for capital to rotate out of these AI direct related markets and into areas that offer more diversification, different sources of return. And look, if that dynamic persists, it does have potential to create a feedback loop where any sort of weakness in AI supports inflows into biotech, and that just further builds on and reinforces the inverse relationship that we've been observing.

[00:04:43] Leonid Timashev: Yeah, those are great points, Rishi. And as we said earlier, biotech's a relatively small part of the S&P 500, including pharma, maybe about 12% versus AI is probably around 50% now. So, any outflows from AI into biotech are easier and more acute to note. And similarly, as [we] mentioned earlier as well, biotech's been traditionally more of a defensive sector. So some of these flows into biotech may be driven less by biotech's core aspects, confidence on clinical catalysts or regulatory, and more by just investors generally looking to defend their positions against volatility.

[00:05:26] Rishi Jaluria: So that's the market side of the story. Now let's turn to the actual science. Where do you see AI having the greatest potential impact on biotech itself?

[00:05:36] Leonid Timashev: In our view, AI can have the greatest impact early in the development process. And the way we think about that is AI can help accelerate molecule discovery, novel chemistry, and potentially help with hypothesis generation and combine data from large datasets across biology, chemistry to generate ideas to test. You know, the other place it can be really helpful is in compiling regulatory documents. Submissions to the FDA can be very large. A lot of them are text and forms, and you know, this is something that large language models probably were in part designed to do. So this is an area where I think AI can accelerate biotech innovation. I think there's a couple of challenges where people expect AI to be helpful, and I think still to be proven. I think a lot of the underlying science still has to be done and verified by humans. And, just because of the highly regulated nature of the industry, you know, if the FDA requires 1 year of animal toxicity or 6 months, and there's not really a lot of ways that that can be accelerated. So there are some timelines that just for regulatory reasons can't necessarily be helped. So, we do see AI as an enabler of innovation, and, you know, maybe bringing that back to the investment thesis, you know, if biotech investors need to pay attention to what's happening in AI, what in your view are the key signals they should be watching?

[00:07:11] Rishi Jaluria: In the report we laid out a number of AI risk dimensions for biotech investors to watch. Our first investor signal is potentially diminishing returns to compute scaling for LLMs. Scaling these AI models is inherently unpredictable. If performance metrics begin to show diminishing returns for the hyperscalers, we could see biotech show a rapid 15% to 20% increase. On the flip side, if the performance continues to improve with scaling and commercial adoption as the more powerful models grow, we could expect to see a gradual rotation back towards the AI trade, potentially contributing to a 15% to 25% contraction in biotech. The underlying issue here is that the results of future scaling really just can't be guaranteed. They really can't be predicted. And I think this creates risk for the AI industry and potentially affects the broader macro landscape. The second area is the momentum of enterprise adoption, and then simultaneously the potential threat that these open weight slash open source models posed to token-based pricing and kind of the premium economics that we see here. If open-weight adoption grows aggressively, it could threaten hyperscaler peak revenue expectations and support that rotation into biotech, and that could drive growth up 15 to 20%. On the flip side, if maybe open-weight market share stabilizes, call it around 35%, we would expect a more incremental impact on biotech. If regulatory restrictions cause open-weight usage to decline, then maybe stronger AI-related performance could drive a 15% to 25% capital rotation back out of biotech. So, in short, changes in token pricing and model adoption could influence how customers use AI, the economics of the AI ecosystem, and the capital available for further development.

[00:09:12] Leonid Timashev: Got it. And then beyond AI performance and adoption itself, what other factors should we be watching?

[00:09:18] Rishi Jaluria: We looked at geopolitical risks to AI supply chains. A resolution to the conflict and normalization in shipping could accelerate AI infrastructure spending, and that could create 5 to 10% downside pressure on biotech, while prolonged disruption could actually modestly benefit biotech. We examined cybersecurity and regulatory risks as well. A rise in AI-related incidents—and we've obviously been reading a lot about these—could increase regulatory scrutiny and create 18% to 20% upside for biotech. And then finally, we looked at AI CapEx. A slowdown in spending could support biotech by 10% to 15%, while continued or accelerated investment in AI could pull capital back into the sector and pressure biotech by 5% to 10%.

[00:10:06] Leonid Timashev: So stepping back, does this suggest that investors need to think less in terms of individual sectors and more about how capital is moving between some of these major sectors and investment themes?

[00:10:19] Rishi Jaluria: Yeah, I think that's exactly right. Look, if you go back to our flagship RBC Imagine report called The Great Recalibration, Forces of Exponential Change. It revealed that AI has concentrated investor returns while dispersion has reached historically high levels, and that has encouraged investors to think laterally across sectors. It also set out that power increasingly flows through data, talent, capital, culture, and trust rather than traditional sector or geographic boundaries. And that is almost a macro-level explanation for what we're discussing today. Sector boundaries matter less when the same pool of capital is rapidly moving between very different industries. If half the healthcare price action can be explained by AI fundamentals, as mentioned earlier, then it's clear that cross-sector capital flows matter more. And investors can no longer assess biotech solely through a healthcare lens. They also need to understand the forces shaping capital allocation across technology, AI, and the wider market.

[00:11:22] Leonid Timashev: That was really informative, Rishi, and thanks for joining me here today. You know, we covered a lot of ground, and there's a lot more to discuss, but that feels like a good place to stop for now. You've been listening to Strategic Alternatives from RBC Capital Markets. This episode was recorded on November 9th, 2026. Listen and subscribe to Strategic Alternatives on Apple, Spotify, or wherever you listen to your podcasts. See you all next time.

This content is based on information available at the time it was recorded. And is for informational purposes only. It is not an offer to buy or sell or a solicitation, and no recommendations are implied. It is outside the scope of this communication to consider whether it is suitable for you and your financial objectives.